Predicted Dysregulated Pathways in MDS-L Cells. MDS-L genomic data was used to generate a map of dysregulated pathways. NRAS mutation is highlighted in blue with mapping of consequent downstream effects. High Copy Number (CN) in red and Low (CN) mutations in purple are also mapped with predicted downstream pathway effects. The totality of dysregulated pathways is predicted to converge on increased cell proliferation and increased cell viability. FDA-approved drugs predicted to impact dysregulated pathways (i.e., celecoxib and nelfinavir) are also shown in the map at critical impact points.